About Butyrophilin-like protein 8
Butyrophilin-like protein 8 (BTNL8) is a protein
from Homo sapiens identified by UniProt accession
Q6UX41, 500 residues long.
MolForge cross-references it against 0 known binders and
34 disease associations.
Target properties
| Protein name | Butyrophilin-like protein 8 |
| UniProt accession | Q6UX41 |
| Gene | BTNL8 |
| Organism | Homo sapiens |
| Length | 500 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (34)
Diseases linked to this target (Open Targets).
- blood protein measurement · score 0.29
- cutaneous melanoma · score 0.12
- Barrett's esophagus · score 0.08
- Pneumothorax · score 0.06
- esophageal adenocarcinoma · score 0.05
- colorectal cancer · score 0.03
- colorectal adenocarcinoma · score 0.03
- neoplasm · score 0.03
- inflammatory bowel disease · score 0.01
- major depressive disorder · score 0.01
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q6UX41-F1 | alphafold | PREDICTED | 86.35 | — |
Amino-acid sequence (500 residues)
MALMLSLVLS LLKLGSGQWQ VFGPDKPVQA LVGEDAAFSC FLSPKTNAEA MEVRFFRGQF SSVVHLYRDG KDQPFMQMPQ YQGRTKLVKD SIAEGRISLR LENITVLDAG LYGCRISSQS YYQKAIWELQ VSALGSVPLI SITGYVDRDI QLLCQSSGWF PRPTAKWKGP QGQDLSTDSR TNRDMHGLFD VEISLTVQEN AGSISCSMRH AHLSREVESR VQIGDTFFEP ISWHLATKVL GILCCGLFFG IVGLKIFFSK FQWKIQAELD WRRKHGQAEL RDARKHAVEV TLDPETAHPK LCVSDLKTVT HRKAPQEVPH SEKRFTRKSV VASQSFQAGK HYWEVDGGHN KRWRVGVCRD DVDRRKEYVT LSPDHGYWVL RLNGEHLYFT LNPRFISVFP RTPPTKIGVF LDYECGTISF FNINDQSLIY TLTCRFEGLL RPYIEYPSYN EQNGTPIVIC PVTQESEKEA SWQRASAIPE TSNSESSSQA TTPFLPRGEM
Explore Butyrophilin-like protein 8 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets